Arcturus Therapeutics (NASDAQ:ARCT) Trading Up 4.7%

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) traded up 4.7% during mid-day trading on Tuesday . The company traded as high as $28.65 and last traded at $28.40. 173,823 shares traded hands during mid-day trading, a decline of 61% from the average session volume of 446,608 shares. The stock had previously closed at $27.13.

Analyst Ratings Changes

A number of equities analysts recently commented on ARCT shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $54.00 price objective on shares of Arcturus Therapeutics in a research report on Tuesday, August 22nd. StockNews.com began coverage on shares of Arcturus Therapeutics in a report on Thursday, August 17th. They issued a “hold” rating for the company. Guggenheim reaffirmed a “buy” rating on shares of Arcturus Therapeutics in a research report on Friday, July 14th. HC Wainwright reiterated a “buy” rating and issued a $51.00 price objective on shares of Arcturus Therapeutics in a research report on Tuesday, September 5th. Finally, William Blair started coverage on Arcturus Therapeutics in a research report on Monday, July 24th. They issued an “outperform” rating and a $71.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Arcturus Therapeutics presently has an average rating of “Hold” and an average target price of $38.78.

Arcturus Therapeutics Stock Up 4.6 %

The firm has a market cap of $754.64 million, a price-to-earnings ratio of 9.39 and a beta of 2.64. The company’s 50-day moving average price is $31.72 and its 200-day moving average price is $27.28.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($1.98) EPS for the quarter, missing the consensus estimate of $0.09 by ($2.07). The business had revenue of $10.52 million during the quarter, compared to analysts’ expectations of $71.05 million. Arcturus Therapeutics had a net margin of 30.36% and a return on equity of 20.75%. On average, sell-side analysts predict that Arcturus Therapeutics Holdings Inc. will post -3.56 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Keith C. Kummerfeld sold 6,968 shares of the business’s stock in a transaction dated Friday, July 14th. The stock was sold at an average price of $35.00, for a total transaction of $243,880.00. Following the completion of the transaction, the insider now directly owns 950 shares of the company’s stock, valued at $33,250. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, COO Pad Chivukula sold 25,000 shares of the company’s stock in a transaction dated Friday, July 14th. The stock was sold at an average price of $35.01, for a total transaction of $875,250.00. Following the completion of the transaction, the chief operating officer now directly owns 519,448 shares of the company’s stock, valued at approximately $18,185,874.48. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Keith C. Kummerfeld sold 6,968 shares of the firm’s stock in a transaction dated Friday, July 14th. The stock was sold at an average price of $35.00, for a total value of $243,880.00. Following the sale, the insider now directly owns 950 shares in the company, valued at approximately $33,250. The disclosure for this sale can be found here. Insiders have sold a total of 41,968 shares of company stock worth $1,420,130 in the last quarter. 13.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Arcturus Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. Bank Julius Baer & Co. Ltd Zurich boosted its stake in Arcturus Therapeutics by 85,285.3% in the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 59,829,489 shares of the biotechnology company’s stock valued at $1,715,910,000 after acquiring an additional 59,759,419 shares in the last quarter. Federated Hermes Inc. boosted its position in shares of Arcturus Therapeutics by 12.7% in the 1st quarter. Federated Hermes Inc. now owns 4,778,500 shares of the biotechnology company’s stock valued at $114,541,000 after purchasing an additional 538,946 shares during the period. State Street Corp grew its stake in Arcturus Therapeutics by 56.5% during the 1st quarter. State Street Corp now owns 3,217,957 shares of the biotechnology company’s stock worth $86,756,000 after buying an additional 1,161,883 shares during the last quarter. BlackRock Inc. increased its position in Arcturus Therapeutics by 10.9% during the second quarter. BlackRock Inc. now owns 1,992,235 shares of the biotechnology company’s stock worth $57,137,000 after buying an additional 195,918 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Arcturus Therapeutics by 12.0% in the third quarter. Vanguard Group Inc. now owns 1,336,818 shares of the biotechnology company’s stock valued at $19,812,000 after buying an additional 143,162 shares during the last quarter. 88.87% of the stock is currently owned by hedge funds and other institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.